Drug Profile
Ondansetron - Transcept Pharmaceuticals
Alternative Names: Setrodon; TO-2061Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Transcept Pharmaceuticals
- Developer Transcept Pharmaceuticals Inc
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Pyrimidinones; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obsessive-compulsive disorders
Most Recent Events
- 17 Jan 2013 Transcept Pharmaceuticals terminates its phase II trial in Obsessive compulsive disorders in USA and Mexico (NCT01275248)
- 21 Dec 2012 Discontinued - Phase-II for Obsessive-compulsive disorders in Mexico (PO)
- 21 Dec 2012 Discontinued - Phase-II for Obsessive-compulsive disorders in USA (PO)